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Background: To compare dosimetric parameters of volumetric modulated arc therapy (VMAT) and non-coplanar
intensity modulated radiotherapy (IMRT) for nasal cavity and paranasal sinus cancer with regard to the coverage of
planning target volume (PTV) and the sparing of organs at risk (OAR).
Methods: Ten patients with nasal cavity or paranasal sinus cancer were re-planned by VMAT (two-arc) plan and
non-coplanar IMRT (7-, 11-, and 15-beam) plans. Planning objectives were to deliver 60 Gy in 30 fractions to 95%
of PTV, with maximum doses (Dmax) of <50 Gy to the optic nerves, optic chiasm, and brainstem, <40 Gy to the eyes
and <10 Gy to the lenses. The target mean dose (Dmean) to the parotid glands was <25 Gy, and no constraints
were applied to the lacrimal glands. Planning was optimized to minimized doses to OAR without compromising
coverage of the PTV. VMAT and three non-coplanar IMRT (7-, 11-, and 15-beam) plans were compared using the
heterogeneity and conformity indices (HI and CI) of the PTV, Dmax and Dmean of the OAR, treatment delivery time,
and monitor units (MUs).
Results: The HI and CI of VMAT plan were superior to those of the 7-, 11-, and 15-beam non-coplanar IMRT. VMAT
and non-coplanar IMRT (7-, 11-, and 15-beam) showed equivalent sparing effects for the optic nerves, optic chiasm,
brainstem, and parotid glands. For the eyes and lenses, VMAT achieved equivalent or better sparing effects when
compared with the non-coplanar IMRT plans. VMAT showed lower MUs and reduced treatment delivery time when
compared with non-coplanar IMRT.
Conclusions: In 10 patients with nasal cavity or paranasal sinus cancer, a VMAT plan provided better homogeneity
and conformity for PTV than non-coplanar IMRT plans, with a shorter treatment delivery time, while achieving equal
or better OAR-sparing effects and using fewer MUs.
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Nasal cavity and paranasal sinus cancers are relatively
rare and account for about 5% of head and neck cancers
[1,2]. Most patients are diagnosed at an advanced stage,
because symptoms and signs are usually nonspecific or
asymptomatic in earlier stages. Standard treatment for
locally advanced nasal cavity and paranasal sinus cancer
is surgery followed by postoperative radiotherapy, or
definitive radiotherapy with or without chemotherapy. In
locally advanced stage, complete resection may not be
possible due to the proximity to critical organs, and
postoperative or definitive radiotherapy is needed. How-
ever, it is challenging to obtain optimal dose coverage
for the target volume without compromising critical
organs due to the proximity of critical organs such as
eyes, optic nerves, optic chiasm, and brain. Intensity-
modulated radiotherapy (IMRT) can provide more
conformal dose coverage for the target volume, with re-
duced dosage to the adjacent critical organs, when com-
pared with two- or three-dimensional radiotherapy [3-7].
Moreover, non-coplanar beams may provide additional
optimization capacity within inverse planning processes
for the target volumes of the nasal cavity and paranasal
sinus cancer, which are usually located between both eyes.
Recently, volumetric modulated arc therapy (VMAT) de-
livered by linear accelerator (LINAC) has become avail-
able. VMAT may reduce treatment delivery time with
lower monitor units (MUs) while providing conformal
dose distribution [8-11].
This study compares VMAT and non-coplanar IMRT
for nasal cavity and paranasal sinus cancers with regard
to the coverage of planning target volume (PTV) and
the sparing of organs at risk (OAR).
Methods
Patients and target volume
Ten patients with nasal cavity or paranasal sinus cancers,
who were previously treated with three-dimensional
radiotherapy or IMRT between April 2011 and April
2013, were randomly selected from a clinical database
maintained by the Asan Medical Center, Seoul, Korea.
Treatment with VMAT (two-arc) and non-coplanar IMRT
(7-, 11-, and 15-beam) was re-planned. Patient character-
istics are shown in Table 1. All patients were T3-4N0M0
according to the American Joint Committee on Cancer
7th staging. Each patient was simulated with a thermo-
plastic mask to immobilize the head and neck. Computed
tomography (CT) images with a 2.5 mm slice thickness
were obtained from vertex to clavicle. For patients previ-
ously treated with definitive radiotherapy, gross tumor
volume (GTV) was defined as all gross disease on the
magnetic resonance imaging (MRI), CT, or positron emis-
sion tomography (PET). Clinical target volumes (CTVs)
included the nasal cavity, ethmoid sinus, frontal sinus, ormaxillary sinus depending on the tumor location and the
extent to cover microscopic spread (Table 1). To compen-
sate for daily set-up variation and motion, the PTV was
defined as the CTV plus a 5 mm margin. Contoured OAR
were the eyes, lenses, optic nerves, optic chiasm, lacrimal
glands, brainstem, brain, and parotid glands.
Planning objectives
The planning objectives were the same for VMAT and
non-coplanar IMRT. The first objective was to deliver a
prescribed dose of 60 Gy in 30 fractions to at least 95%
of the PTV. Second, both treatments were planned with
a maximum dose (Dmax) of <50 Gy to the optic nerves,
optic chiasm, and brainstem, <40 Gy to the eyes
and <10 Gy to the lenses. The planned mean dose (Dmean)
to the parotid glands was < 25 Gy, and no constraint was
applied to the lacrimal glands. Third, treatment planning
aimed to reduce doses to OAR as much as possible with-
out compromising the coverage of the PTV.
Priority of optimization was same as the order of plan-
ning objectives mentioned above. We put the highest
priority to the maximum and minimum doses of PTV.
For OARs, we put higher priority to the maximum doses
of optic nerves, eyes, and lenses because these organs
were very close to the PVT. After optimization, actual
dose distributions in PTV and OARs were checked
by dose statistics, dose volume histograms, and 3-
dimensional isodose lines whether planning objectives
were met. If the optimization result was not acceptable,
we modified optimization parameter such as priority and
dose constraint and performed optimization again.
VMAT planning
For both VMAT and non-coplanar IMRT plans, 6 MV
photon beams were applied using a Varian TrueBeam
STx (Varian Medical System, Palo Alto, CA), with multi-
leaf collimators (MLCs) comprising 120 leaves of 2.5 mm
width (in sliding window mode). Dose calculations were
performed by Anisotropic Analytic Algorithm with a
maximum dose rate of 600 MU/min. VMAT plans were
created using the two-arc technique, and optimization
was performed using Eclipse progressive resolution
optimization (version 10.0.28). The first arc ranged from
181° to 179° in clockwise rotation, and the second arc
was from 179° to 181° in counter-clockwise rotation.
The collimator angle was 30° for the first arc and 330°
for the second arc.
IMRT planning
Eclipse dose volume optimization (version 10.0.28) was
used for IMRT planning. To estimate the optimal num-
ber and angles of beams in non-coplanar IMRT plans
for nasal cavity and paranasal sinus cancers, a beam
angle optimization process was performed for 5 patients
Table 1 Patient characteristics
Case Primary site Stagea Aim of radiotherapy Clinical target volume
1 Nasal cavity T4aN0M0 Definitive Nasal cavity, ethmoid, frontal sinus, ipsilateral maxillary sinus
2 Nasal cavity T4aN0M0 Definitive Nasal cavity, ethmoid, frontal sinus, ipsilateral maxillary sinus
3 Maxillary sinus T4aN0M0 Definitive Nasal cavity, ipsilateral maxillary sinus
4 Maxillary sinus T4aN0M0 Postoperative Nasal cavity, ethmoid, frontal sinus, ipsilateral maxillary sinus
5 Nasal cavity T4aN0M0 Postoperative Nasal cavity, ethmoid, frontal sinus, ipsilateral maxillary sinus
6 Ethmoid T4bN0M0 Postoperative Nasal cavity, ethmoid, frontal sinus, bilateral maxillary sinus
7 Maxillary sinus T3N0M0 Postoperative Nasal cavity, ipsilateral maxillary sinus
8 Nasal cavity T4aN0M0 Definitive Nasal cavity, ethmoid, frontal sinus, ipsilateral maxillary sinus
9 Nasal cavity T3N0M0 Postoperative Nasal cavity, ethmoid, frontal sinus, bilateral maxillary sinus
10 Nasal cavity T4bN0M0 Postoperative Nasal cavity, ethmoid, frontal sinus, ipsilateral maxillary sinus
aAccording to American Joint Committee on Cancer 7th staging.
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was automatic process which is supported by Eclipse dose
volume optimization (version 10.0.28). The optimal num-
ber of beams varied from 5 to 15 in each patient, and the
beams were concentrated in the anterior direction, sparing
both eyes and lenses. Based on these results, three non-
coplanar IMRT (7-, 11-, and 15-beam) plans were devel-
oped for each patient. The 7-beam IMRT consisted of 5
coplanar beams at gantry angles of 0°, 30°, 100°, 260°, and
330°, and 2 non-coplanar vertex beams at gantry angles of
30° and 330° with a 90° couch rotation. The collimator
angle was 30° for the 2 coplanar beams at gantry angles of
30° and 100°, 330° for the 2 coplanar beams at gantry
angles of 260° and 330°, and 0° for the other beams. The
11-beam IMRT used 9 coplanar beams at gantry angles of
0°, 20°, 40°, 60°, 100°, 260°, 300°, 320°, and 340°, and 2
non-coplanar vertex beams at gantry angles of 30° and
330° with a 90° couch rotation. The collimator angle was
30° for the 4 coplanar beams at gantry angles between 20°
and 100°, 330° for the 4 coplanar beams at gantry angles
between 260° and 340°, and 0° for other beams. The 15-
beam IMRT comprised 11 coplanar beams at gantry an-
gles of 0°, 15°, 30°, 45°, 60°, 100°, 260°, 300°, 315°, 330° and
345°, and 4 non-coplanar vertex beams at gantry angles of
15°, 30°, 330° and 345° with a 90° couch rotation. The
collimator angle was 30° for the 5 coplanar beams at
gantry angles between 15° and 100°, 330° for the 5 copla-
nar beams at gantry angles between 260° and 345°, and 0°
for other beams.
Plan evaluation and statistics
PTV coverage was compared between VMAT and non-
coplanar IMRT (7-, 11-, and 15-beam) using the hetero-
geneity index (HI) and conformity index (CI). The HI of
PTV was defined as:
HI = (D5% - D95%)/Dmean
D5% and D95% are the minimum doses delivered to 5%
and 95% volume of the PTV, and Dmean is the meandose. A greater HI means higher heterogeneity. The CI
of PTV was defined as:
CI = VTV/VPTV
where VTV is the treatment volume enclosed by the
prescribed 60 Gy isodose surface, and VPTV is the vol-
ume of the PTV. A greater CI indicates lower conform-
ity. To compare the OAR sparing of the VMAT and
each of non-coplanar IMRT plans, Dmax was evaluated
for the eyes, lenses, optic nerves, optic chiasm, lacrimal
glands, and the brainstem, and the Dmean of the parotid
glands was recorded. Mean dose volume histograms
(DVHs) for the PTV and OAR were calculated. MUs
and treatment time for 2 Gy were also evaluated. We de-
fined treatment delivery time in each patient as the sum
of the beam on time with gantry rotation and beam
setup time for VMAT plans and as the sum of the beam
on time, beam setup time, and couch rotation time for
non-coplanar IMRT plans, respectively. To estimate real
treatment delivery time consisting of beam on time,
beam setup time, and couch rotation time, VMAT and
non-coplanar IMRT plans were delivered on Varian
TrueBeam STx in quality assurance mode. Wilcoxon
signed-rank tests were performed to compare the above
parameters between the VMAT plan and each of the
non-coplanar IMRT (7-, 11-, and 15-beam) plans. All
statistical tests were two-sided and performed at the 5%
level of significance using SPSS (version 18.0).
Results
Planning target volume coverage
The HI and CI of VMAT and each of the 7-, 11-, and
15-beam non-coplanar IMRT plans for each of the 10
patients are shown in Figures 1 and 2. The HIs of the
VMAT plan were better than those of the 7-, 11-, and
15-beam non-coplanar IMRT plans (mean HI 0.07 vs.
0.10 vs. 0.09 and 0.10, respectively, p = 0.004, p = 0.012,
and p = 0.005; Table 2). The CI was also superior in
VMAT plans compared with each of 7-, 11-, 15-beam
Figure 1 Comparison of the heterogeneity indices of
volumetric modulated arc therapy (VMAT) and non-coplanar
intensity modulated radiotherapy (IMRT; 7-, 11-, and 15-beam).
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1.10 and 1.10, respectively, p = 0.002, p = 0.008, and p =
0.016) (Table 2). The mean DVHs for PTVs are shown
in Figure 3.
Dose to organs at risk
The doses delivered to the various OAR by the VMAT
plan and each of the 7-, 11-, and 15-beam non-coplanar
IMRT plans for each of 10 patients are shown in
Figure 4. The VMAT plan and the non-coplanar IMRT
(7-, 11-, and 15-beam) plans showed equivalent sparing
effects for the optic nerves, optic chiasm, brainstem, and
parotid glands. For the eyes and lenses, VMAT achieved
better or equivalent sparing effects when compared with
each of the non-coplanar IMRT plans (Table 2). The
maximum doses to the eyes of the VMAT plan were
equivalent to those of the 11-beam non-coplanar IMRT
plan (mean Dmax of ipsilateral eye, 43.1 Gy vs. 46.1 Gy,Figure 2 Comparison of the conformity indexes of volumetric
modulated arc therapy (VMAT) and non-coplanar intensity
modulated radiotherapy (IMRT; 7-, 11-, and 15-beam).p = 0.064; mean Dmax of contralateral eye, 41.1 Gy vs.
42.7 Gy, p = 0.492), but lower than those of the 7-beam
non-coplanar IMRT plan (mean Dmax of ipsilateral eye,
43.1 Gy vs. 48.8 Gy, p = 0.004; mean Dmax of contrala-
teral eye, 41.1 Gy vs. 44.7 Gy, p = 0.004). For lenses,
VMAT had an equivalent sparing effect to the 7-beam
non-coplanar IMRT plan (mean Dmax of ipsilateral lens,
10.5 Gy vs. 12.1 Gy, p = 0.193; mean Dmax of contralat-
eral lens, 10.2 Gy vs. 11.6 Gy, p = 0.193) and a better
sparing effect than 15-beam non-coplanar IMRT plan
(mean Dmax of ipsilateral lens, 10.5 Gy vs. 13.6 Gy, p =
0.002; mean Dmax of contralateral lens, 10.2 Gy vs.
12.6 Gy, p = 0.006). For lacrimal glands which no con-
straints were applied during treatment planning, each of
the non-coplanar IMRT plans showed better Dmax and
D1% than VMAT (Table 2). The mean DVHs for OAR
are shown in Figure 3. Although DVHs for the optic
chiasm, lenses, and lacrimal glands showed a similar
trend to the Dmax, the DVHs for the optic nerves and
eyes were better in non-coplanar IMRT, and the DVHs
for brainstems were better in VMAT.
MUs and treatment delivery times
Mean MU was significantly lower in the VMAT plan than
for each of 7-, 11-, 15-beam non-coplanar IMRT plans
(485 vs. 2224 vs. 2350 and 2475, respectively; p = 0.002, p =
0.002, and p = 0.002). The mean beam on time was shorter
in the VMAT plan than in the 7-, 11-, and 15-beam non-
coplanar IMRT plans (2.48 minutes vs. 3.71 minutes vs.
3.92 minutes and 4.13 minutes, respectively; p = 0.002, p =
0.002, and p = 0.002). The estimated beam setup time was
1.86 minutes in VMAT plans and 6.51 minutes, 10.23 mi-
nutes, and 13.95 minutes in each of 7-, 11-, and 15-beam
non-coplanar IMRT plans, respectively. In non-coplanar
IMRT plans, the couch rotation time was estimated as
1.5 minutes. The entire treatment delivery time was
estimated shorter in VMAT plan than in the 7-, 11-, and
15-beam non-coplanar IMRT plans (mean, 4.34 minutes
vs. 11.72 minutes vs. 15.65 minutes and 19.58 minutes,
respectively; p = 0.002, p = 0.002, and p = 0.002) (Table 2).
Discussion
In this study, the VMAT plan had better conformity and
homogeneity with the PTV and equivalent to better
sparing effects on OAR than the non-coplanar IMRT
plans (7-, 11-, and 15- beam), for radiotherapy of nasal
cavity and paranasal sinus cancers. The nasal cavity and
paranasal sinus are adjacent to critical organs such as
the eyes, optic nerves, optic chiasm, and brain. Opti-
mizing dose coverage for the target volume without
compromising critical organs is therefore a challenge in
treatment planning. Previously, two-dimensional radio-
therapy (2D-RT) with a weighted anterior field and two
wedged lateral fields, and three-dimensional conformal













p value (VMAT vs.)
7-beam IMRT 11-beam IMRT 15-beam IMRT
HI of PTV 0.07 (0.01) 0.10 (0.03) 0.09 (0.03) 0.10 (0.02) 0.004* 0.012* 0.005*
CI of PTV 1.05 (0.03) 1.13 (0.03) 1.10 (0.05) 1.10 (0.04) 0.002* 0.008* 0.016*
Ipsilateral optic nerve Dmax (Gy) 47.9 (2.16) 46.9 (3.15) 46.3 (3.21) 46.0 (3.91) 0.492 0.492 0.193
D1% (Gy) 45.7 (2.36) 44.1 (2.95) 43.0 (2.40) 43.1 (3.17) 0.322 0.084 0.064
Contralateral optic nerve Dmax (Gy) 47.0 (2.86) 46.0 (2.86) 46.8 (2.79) 46.0 (2.87) 0.275 0.695 0.322
D1% (Gy) 45.3 (2.65) 43.1 (2.79) 44.2 (2.21) 43.6 (2.55) 0.129 0.275 1.000
Optic chiasm Dmax (Gy) 46.7 (2.64) 45.3 (3.46) 45.6 (2.67) 45.0 (2.87) 0.275 0.322 0.193
D1% (Gy) 46.6 (2.48) 42.7 (3.01) 42.9 (2.45) 42.5 (2.96) 0.193 0.166 0.131
Brainstem Dmax (Gy) 44.2 (3.31) 46.0 (2.33) 44.5 (2.45) 45.1 (2.24) 0.105 0.770 0.322
D1% (Gy) 39.8 (3.05) 41.7 (1.77) 40.9 (1.77) 41.8 (1.62) 0.160 0.359 0.064
Ipsilateral eye Dmax (Gy) 43.1 (3.56) 48.8 (4.51) 46.1 (4.59) 45.9 (3.30) 0.004* 0.064 0.037*
D1% (Gy) 38.8 (3.45) 39.8 (3.89) 37.6 (3.36) 37.4 (2.56) 0.322 0.322 0.275
Contralateral eye Dmax (Gy) 41.1 (3.15) 44.7 (2.94) 42.7 (4.37) 42.4 (3.86) 0.004* 0.492 0.322
D1% (Gy) 36.7 (3.70) 35.7 (2.89) 34.4 (4.03) 33.9 (3.84) 0.264 0.078 0.064
Ipsilateral lens Dmax (Gy) 10.5 (1.36) 12.1 (2.28) 12.6 (1.99) 13.6 (1.79) 0.193 0.020* 0.002*
D1% (Gy) 9.77 (1.19) 11.9 (2.32) 12.2 (2.10) 13.3 (1.96) 0.014* 0.006* 0.002*
Contralateral lens Dmax (Gy) 10.2 (1.17) 11.6 (2.18) 11.8 (2.19) 12.6 (2.12) 0.193 0.084 0.006*
D1% (Gy) 9.49 (0.93) 11.2 (2.36) 11.4 (2.26) 12.2 (2.29) 0.053 0.012* 0.04*
Ipsilateral lacrimal gland Dmax (Gy) 28.5 (10.3) 15.2 (6.37) 18.1 (9.93) 16.5 (6.27) 0.004* 0.004* 0.002*
D1% (Gy) 27.1 (1.02) 14.1 (5.50) 17.0 (9.41) 15.4 (5.71) 0.002* 0.004* 0.002*
Contralateral lacrimal gland Dmax (Gy) 22.1 (4.44) 11.4 (6.06) 12.4 (6.02) 11.0 (5.27) 0.002* 0.002* 0.002*
D1% (Gy) 21.0 (4.69) 10.8 (5.77) 11.3 (5.74) 10.4 (5.17) 0.002* 0.002* 0.002*
Ipsilateral parotid gland Dmean (Gy) 12.5 (9.91) 12.2 (8.75) 12.7 (8.93) 11.8 (8.45) 0.922 0.625 0.625
Contralateral parotid gland Dmean (Gy) 9.84 (7.80) 8.84 (6.87) 9.27 (6.80) 8.07 (5.87) 0.131 0.492 0.084
Monitor units 485 (66.3) 2224 (423) 2350 (451) 2475 (384) 0.002* 0.002* 0.002*
Treatment delivery time (Minutes) 4.34 (0.00) 11.72 (0.71) 15.65 (0.75) 19.58 (0.64) 0.002* 0.002* 0.002*
*p value < 0.05.
PTV, planning target volume; OARs, organs at risk; MUs, monitor units; SD, standard deviation; HI, heterogeneity index; CI, conformity index; Dmax, maximum dose;
Dmean, mean dose; D1%, minimum dose delivered 1% of the PTV.
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and to overcome dose heterogeneity. However, the com-
plex shape and tissue heterogeneity of the target volume
negatively affect dose distribution, and treatment out-
comes were unsatisfactory in terms of local control and
optic pathway preservation [7]. With the development of
computerized optimization processes, techniques with
more conformal and homogeneous dose distributions
have become possible. These include IMRT, a form of
3D-CRT able to generate non-uniform intensity using
beamlets. Several studies have compared IMRT to 2D-
RT or 3D-CRT for the treatment of nasal cavity and
paranasal sinus cancer [3-7]. Lee et al. compared IMRT
using the complementary boost-fields with 3D-CRT for
ethmoid sinus cancer [4]. The homogeneity of the PTV
was higher for IMRT than for 3D-CRT, and OARsparing was similar. Other studies also reported that
IMRT improved PTV coverage and/or OAR sparing
[3,5-7]. However, IMRT needs more MUs and longer
treatment delivery time than 2D-RT or 3D-CRT, and it
has inevitable disadvantages. Wang et al. evaluated the
impact of prolonged treatment delivery time on tumor
control in a biologic model, and calculated that cell
killing was decreased with prolonged treatment delivery
time, especially in tumors with low alpha/beta ratios or
short repair half-times [12]. Although there are no
clinical studies to date, several studies have shown the
detrimental effect of prolonged treatment delivery time
using cell lines or xenograft models [13-17].
VMAT allows rapid delivery of inverse planned radio-
therapy by continuous gantry rotation and simultaneous
modulation of MLCs, and has recently become available.
Figure 3 Mean dose volume histograms (DVHs) for planning target volume (PTV) and organs at risk in volumetric modulated arc
therapy (VMAT) and non-coplanar intensity modulated radiotherapy (IMRT) using 7-, 11-, and 15-beams. (A) PTV; (B) ipsilateral optic
nerve; (C) contralateral optic nerve; (D) optic chiasm; (E) brainstem; (F) ipsilateral eye; (G) contralateral eye; (H) ipsilateral lens; (I) contralateral
lens; (J) ipsilateral lachrymal gland; (K) contralateral lachrymal gland; (L) ipsilateral parotid gland; and (M) contralateral parotid gland.
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IMRT in terms of dose coverage, OAR-sparing effects,
reduced treatment delivery time and decreased MUs[8-11]. In these studies, VMAT showed equivalent or
better PTV coverage and OAR-sparing effects, decreased
treatment delivery time and fewer MUs [8-11].
Figure 4 Comparison of dose distribution in organs at risk for
volumetric modulated arc therapy (VMAT) and non-coplanar
intensity modulated radiotherapy (IMRT; 7-, 11-, and 15-beam).
IL, ipsilateral; CL, contralateral; Dmax, maximum dose; Dmean, mean
dose; ON, optic nerve; OC, optic chiasm; LG, lachrymal gland; PG,
parotid gland.
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and paranasal sinus cancers, which are usually located
between both eyes and have complex shaped target vol-
umes [18-21]. The dosimetric superiority of VMAT for
PTV coverage and OAR sparing shown in the present
study are consistent with most previous studies. Sankar-
alingam et al. compared VMAT (two-arc) and coplanar
IMRT (5-beam, sagittal) in nasal cavity and paranasal
sinus cancer (n = 5) and reported that VMAT showed
better homogeneity in all patients and better conformity
in 3 of 5 patients. However, the number of patients was
too small to establish statistically significant differences
[19]. In another study, step-and-shoot IMRT was com-
pared with single arc and multiple arc VMAT for local-
ized prostate cancers (n = 5), pharyngeal cancers (n =
10), and paranasal sinus cancers (n = 5) [18]. VMAT
showed equivalent or improved PTV coverage, homo-
geneity, conformity, and OAR sparing when compared
with step-and-shoot IMRT in localized prostate cancers
and pharyngeal cancers, but not in paranasal sinus can-
cer patients, where increased doses to the lenses were
observed in VMAT using multiple arcs. More recently,
Nguyen et al. reported a dosimetric comparative study
which compared VMAT (3-arc) and IMRT (9-beam) for
nasal cavity cancer (n = 10) [20]. In that study, VMAT
showed comparable PTV coverage and equivalent or
better reduced dose to the OARs as well as fewer MUs
and shorter treatment delivery times. Similarly, VMAT
showed equivalent PTV coverage to IMRT with de-
creased delivery times and MUs in 20 patients with head
and neck cancers [21]. It is difficult to compare these
studies directly because of differences in the target
volumes, prescribed doses, number of prescribed dose
levels, planning algorithm, plan evaluation methods, andsmall numbers of patients. However, VMAT shows bet-
ter or equivalent PTV coverage and OAR-sparing effects
in all studies except that of Guckenberger et al.
VMAT has greater freedom for optimization when
compared with IMRT, as it allows gantry rotation with
variable speed during treatment delivery, simultaneous
MLC modification and simultaneous dose rate variation
[22-25]. However, in nasal cavity and paranasal sinus
cancer patients, whose target volumes are usually lo-
cated between the eyes, the benefits of gantry rotation
may be limited due to the relative limitations on beam
angle selection. This could increase low-dose ‘tails’ to
the lenses, and may account for the observations in
Guckenberger et al. [18]. The present study evaluated
whether the optimization freedom benefits of VMAT
were realizable in nasal cavity or paranasal sinus cancers,
or whether non-coplanar IMRT remained superior for
PTV coverage and OAR sparing in that area. Three non-
coplanar IMRT (7-, 11-, and 15-beam) plans were imple-
mented for each patient, none of which were superior to
VMAT in PTV coverage. All three IMRT plans had
greater Dmax and Dmean, and worse mean DVH, for both
lenses. Non-coplanar, multi-beam fixed beam IMRT may
not therefore overrule the optimization freedom of
VMAT, even if the number and angle of beams are opti-
mal. Moreover, in the present study, beams from the
posterior direction were the most limited because of the
brainstem and brain. The superiority of the VMAT plan
might also arise from this limitation of the posterior
beams in the non-coplanar IMRT plans, but further
studies using more posterior direction beams are needed
to confirm this suggestion.
This study has several limitations. First, it is a planning
study comparing the dosimetric parameters between
non-coplanar IMRT and VMAT. Local control and tox-
icities can be influenced by various factors such as past
medical history, histologic types, and combination with
chemotherapy as well as by dosimetric parameters.
Whether the superiority of VMAT can be translated into
clinical benefit is therefore not clear. Several studies
have reported that dosimetric improvement from 2D-RT
or 3D-CRT to IMRT resulted in clinical benefit with
respect to local control and toxicities, and technical
advances within IMRT may also result in clinical im-
provements [7,26-28]. However, the relative dosimetric
superiority of VMAT to IMRT may be smaller than that
of IMRT to two- or three-dimensional radiotherapy, and
may not result in clinical difference. Moreover, in
present planning study, there is also a general weakness
that results may not be consistent when the calculation
and/or optimization algorithms are changed. Second, the
two-arc approach was used for VMAT planning whereas
7-, 11-, and 15-beam IMRT was planned. A single arc
VMAT plan can be sufficient for areas with less complex
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However, for complex target areas or multiple dose
prescription levels, the two-arc technique was needed to
achieve PTV coverage and OAR sparing better than or
equivalent to fixed beam IMRT, and single arc VMAT
was inferior to fixed beam IMRT [10,11,18,32,33]. Nasal
cavity and paranasal sinus cancers have complex target
volume shapes, and so two-arc VMAT was chosen for
the current study. Two-arc VMAT was equivalent to or
better than non-coplanar IMRT in this setting. However,
further studies of the details of VMAT such as the gan-
try rotation angle, number of arcs, and using non-
coplanar arcs are needed. Third, the current study used
a single-dose prescription level. The differences between
VMAT and non-coplanar IMRT when performing simul-
taneous integrated boost techniques with multiple dose
prescription level was not evaluated, and further studies
are needed. Fourth, present study did not reflect the dif-
ference in the treatment delivery error between VMAT
and non-coplanar IMRT. Although there has been no
definite conclusion about the influence of delivery error
yet, random and systematic errors of MLC position, gan-
try position, and MU are present in both VMAT and
non-coplanar IMRT plans. Furthermore, couch rotation
errors and intrafraction setup errors are also present in
non-coplanar IMRT plans. Despite these shortcomings,
the present study is one of a small number comparing
VMAT with IMRT for nasal cavity and paranasal sinus
cancers, and was performed in a relatively large number
of patients. Attempts were made to reduce bias in sev-
eral ways. First, all patients were re-planned for VMAT
and non-coplanar IMRT, instead of using previous plans.
Second, the same planning objectives were applied for
VMAT and non-coplanar IMRT. Third, dose calculations
were performed using the Anisotropic Analytic Algo-
rithm. Furthermore, the MLC with 2.5 mm width in the
Varian TrueBeam STx apparatus used in this study en-
ables more precise plans for the complex shaped target
volumes of nasal cavity and paranasal sinus cancers.
Conclusions
In patients with nasal cavity or paranasal sinus cancer,
VMAT provided better homogeneity and conformity for
PTV than 7-, 11-, and 15- beam non-coplanar IMRT
plans, while achieving equal or better OAR-sparing effects,
using fewer MUs and shortening treatment delivery times.
VMAT can therefore be considered a good treatment
option for nasal cavity and paranasal sinus cancers.
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